What Happened?
Research Triangle Park, -based G1-Therapeutics Resigned Stillman Hanson as General Counsel
Date of management change: May 22, 2023
Research Triangle Park, -based G1-Therapeutics Resigned Stillman Hanson as General Counsel
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.
Stillman Hanson is General Counsel at Fortrea. Previously, Stillman held various senior legal leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Bouc David, Reissland Gaibrelle, Glasunow Allison, Gremillion Julie, Sobon Wayne, Pawelka Leslie, Schwartz Jeffery, Kelley Mary, Kouyoumdjian Aram, Gorman Claire, Fadden Kathleen
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.